It has long-term discovery alliances with Bristol Myers Squibb,[4] Bayer,[5] Sanofi,[6] Boehringer Ingelheim,[7] the CHDI Foundation,[8] Lilly,[9] Takeda,[10] Sernova,[11] and more.

The following year, it merged with the British chemical services company Oxford Asymmetry International plc,[18] adopting the new name Evotec OAI.

Four years later, this division was sold to PerkinElmer[19] in a move that, according to Evotec, allowed it to focus its resources towards the discovery and development of new pharmaceutical drugs.

One year later, the company announced it was voluntarily de-listing its American Depositary Receipt to cut costs and concentrate its share trading on the German TecDAX platform.

[22] In 2010, the company acquired DeveloGen AG,[23] a spin-out from the Max Planck Institute for Biophysical Chemistry that was developing novel therapies for metabolic disorders, such as diabetes.

Evotec's initial focus will be on antimicrobial resistance ("AMR") and superbug infections, tuberculosis, and malaria, as well as the creation of novel antiviral therapies with new mechanisms of action.

[33] In June 2020, Evotec and two investment partners – Samsara BioCapital and KCK Ltd. – announced the launch of Autobahn Labs, a virtual incubator for early-stage research programs, headquartered in Palo Alto, California.